Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1396 to 1410 of 2208 results for guidelines

  1. Lung cancer: Treatment pathways

    pathways bringing together NICE recommended treatment options from this guideline and relevant technology appraisal guidance on advanced...

  2. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022

  3. What training, support or interventions help to reduce caring-related accidents or incidents?

    are included in the psychological and emotional support section of this guideline.By consensus, the committee also agreed to add some...

    Research recommendation
    Published
    10 February 2020

  4. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    and cost effectiveness. The cost-effectiveness model developed for this guideline combined evidence of clinical effectiveness, costs and...

    Research recommendation
    Published
    9 June 2015

  5. Is obesity an independent risk factor for perinatal morbidity and mortality?

    the woman's preference and obstetric indications in line with the NICE guideline on intrapartum care for health women and babies . There...

    Research recommendation
    Published
    16 August 2019

  6. Organisation of care:- What is the clinical and cost effectiveness of alternative approaches to organising primary care compared with usual care for people with multimorbidity?

    Any explanatory notes(if applicable) Why this is important:- The guideline committee felt that primary care was well suited to managing...

    Research recommendation
    Published
    18 October 2016

  7. TearLab osmolarity system for diagnosing dry eye disease (MIB47)

    NICE has developed a medtech innovation briefing (MIB) on TearLab osmolarity system for diagnosing dry eye disease .

    Medtech innovation briefing
    Published
    15 December 2015

  8. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

    Technology appraisal guidance
    Published
    20 April 2023
    View recommendations

    Sections for TA880

  9. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    25 March 2014
    View recommendations

    Sections for TA307

  10. What are the information and support needs of parents and carers with babies on parenteral nutrition?

    as encouraging shared decision making, are covered in the NICE clinical guideline on patient experience in adult NHS services. Given...

    Research recommendation
    Published
    17 March 2020

  11. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  12. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

    Technology appraisal guidance
    Published
    25 August 2021
    View recommendations

    Sections for TA722

  13. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG484

  14. What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration of follow‑up, frequency of follow‑up appointments, the type of examination or blood tests, and the roles of primary and secondary care in follow‑up?

    committee agreed that the 2‑year follow‑up recommended in the previous guideline was conservative, and based on their expertise, people...

    Research recommendation
    Published
    25 October 2019

  15. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

    Medtech innovation briefing
    Published
    13 December 2022